Introduction
Parkinson's disease, a common neurodegenerative disease, typically begins with one of three cardinal motor symptoms of tremor, rigidity or bradykinesia and ultimately leads to deterioration of gait and balance, as well as other motor and nonmotor signs that may result in a state of immobility if left untreated. Bradykinesia correlates well with the loss of dopamine in the striatum due to degeneration of nigrostriatal neurons. Other morphologic and chemical de®cits have also been demonstrated in the brains of patients with Parkinson's disease in the cholinergic pedunculopontine nucleus, noradrenergic locus coeruleus, serotonergic raphe nuclei and glutamatergic centromedian/parafascicularis complex of the thalamus. These de®cits are hypothesized to explain the noncardinal clinical features of the disease.
The cause of Parkinson's disease is still unknown, but the discovery of multiple pathogenic mechanisms and etiologies has contributed to the notion that Parkinson's disease is not a single entity, but that there are several forms of the disease. Although well de®ned genetic abnormalities account for only a minority of cases, there is a growing body of evidence that susceptibility genes and other genetic mechanisms may play a role in the pathogenesis of a substantial number of Parkinson's disease cases [1 . ]. A strong case can also be made for an environmental origin or an interaction of environment and genetics in the majority of cases [2] . It is hypothesized that these genetic or environmental initiating factors result in abnormal protein folding and subsequent abnormal proteasomal processing, resulting in accumulation of toxic protein products precipitating a degenerative process that involves oxidative stress leading to mitochondrial injury (especially complex I) and cell death. This ultimately results primarily in nigrostriatal degeneration and secondarily in increased activity in the indirect, striatum-globus pallidus externum (GPe) pathway. Furthermore, increased activity occurs in the glutamatergic pathway projecting from the subthalamic nucleus (STN) to the globus pallidus internum (GPi), coupled with decreased activity of the direct, striatum±GPi pathway. This model predicts that in Parkinson's disease there is increased activity of the basal ganglia out¯ow nucleus, GPi, and consequent inhibition of the thalamo-cortical-spinal pathway expressed clinically as bradykinesia.
The ultimate goals of treatment include protection from destruction by the degenerative process (neuroprotection), rescue of dying neurons, and replacement or at least functional restoration of damaged pathways and neuronal elements. Although these are achievable goals, the current strategies focus on control of symptoms of the disease and prevention or treatment of the complications of symptomatic agents.
Neuroprotection
Many compounds have been shown to prevent neurodegeneration in cultured cell lines or animal models of Parkinson's disease. These compounds include (1) direct antioxidants (e.g. vitamins E and C), (2) antiin¯ammatory compounds (e.g. cyclooxygenase-2 inhibitors), (3) trophic factors (glial cell line-derived neurotrophic factor (GDNF) and its inducer vitamin D 3 ), (4) coenzyme Q, and (5) antiapoptotic compounds, including the caspase inhibitor minocycline. There are a number of drugs that indirectly decrease oxidative stress by altering neuronal activity, such as dopamine agonists [3] , nicotine and caffeine [4] and possibly g-aminobutyric acid agonists and glutamate antagonists. Many of these drugs are potential candidates not only for neuroprotection but also for symptomatic treatment. The neuroimmunophilin ligands, derived from immunosuppressant agents such as cyclosporine and FK506, may exert neurotrophic properties in neural injury models and protect against lesions in rodent models [5] . These agents, however, have not yet been found effective in a primate, nmethyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease [6] or in clinical trials. Earlier suggestions that deprenyl, also known as selegiline, has neuroprotective effects have been discounted after examining the long-term outcomes of treated patients, although the most recent study throws further confusion into this issue [7 . ]. The drug does, however, delay the need for levodopa and as such may be a reasonable drug to use in the earliest stages of Parkinson's disease. At the present time there are insuf®cient data to recommend any speci®c regimen for neuroprotection [8 . ].
Symptom control
Strategies for symptom control include replacement or mimicking of dopamine; modulating the actions of other neurotransmitters within the basal ganglia, in particular glutamate and acetylcholine, and surgery.
Levodopa
Levodopa, which potentiates dopaminergic transmission, remains the most effective symptomatic agent, but its bene®ts are limited both because of dopa-related complications and emergence of dopa-resistant symptoms, such as gait and balance problems, freezing, dysphagia, cognitive decline, and dysautonomia [9] . Levodopa, in combination with an inhibitor of Laromatic amino acid decarboxylase (DDI) is effective in the treatment of tremor, rigidity and bradykinesia. Since many of the problems seen in patients on long-term levodopa therapy, speci®cally motor¯uctuations, can be relieved at least temporarily with continuous intravenous levodopa infusion, agents and techniques have been developed to provide constant plasma levodopa concentrations. It has been hypothesized that marked¯uctuations of dopaminergic stimulation resulting in pulsatile activation of postsynaptic dopamine receptors are nonphysiologic and result in plastic changes in the striatum and downstream structures that correlate with untoward complications of dopaminergic therapy [10]. These ®ndings have contributed to the pharmacologic therapeutic strategy advocating`continuous dopaminergic stimulation'.
Levodopa is available in several formulations including regular' tablets, slow or controlled release formulations, and it can also be dissolved in aqueous solutions. Controlled release preparations result in relatively constant plasma levodopa levels for about 6 h in a normal gastrointestinal tract. These preparations are preferred by patients with mild to moderate Parkinson's disease who do not yet experience dopa-induced dyskinesias [11] . Later in the course of the disease, gastrointestinal motility becomes variable and levodopa absorption erratic. It is reasonable to start with controlled release preparations and to continue with these until the response becomes less predictable (possibly as a result of erratic absorption) or until the ®rst sign of dyskinesia. At that point, it may be preferable to switch the patient to immediate release (`regular') levodopa and, if needed, instruct the patient to chew the medicine or dissolve it in liquid, taking small quantities at very frequent intervals. This simulates the effect of a continuous intravenous infusion. A duodenal infusion system results in good smoothing out of the response for up to 7 years, but it is cumbersome [12 . . ].
Catechol-O-methyltransferase inhibitors
When levodopa is taken alone, 99% is metabolized peripherally; adding a DDI reduces that ®gure to 90%, still making most of the ingested drug unavailable to the brain. Peripheral conversion to 3-o-methyl-dopa by catechol-O-methyltransferase (COMT) also reduces bioavailability of levodopa in the brain. Two COMT inhibitors are currently available ± tolcapone, which acts both centrally and peripherally, and entacapone, which acts only peripherally. These agents result in an increased plasma levodopa t rather than C max and increased`on' time in patients with¯uctuations. Tolcapone has been implicated in possible liver damage in a very small number of patients, which has resulted in a dramatic reduction in its usage, to the point of cessation in many countries. It has been argued, however, that tolcapone has some advantages over entacapone and that it still has utility in the treatment of Parkinson's disease patients with motor¯uctuations. Some investigators have argued the gain in clinical improvement with tolcapone can be fully explained by changes of peripheral levodopa pharmacokinetics [13] .
Earlier double-blind trials have demonstrated that entacapone reduces`off' time in patients with temporal uctuations [14] . A large open trial of entacapone extended these results to conditions of daily neurological practice [15] . A double-blind, placebo-controlled, randomized, crossover, study in 25 patients compared 100, 200, and 400 mg of entacapone with placebo (four to six doses per day with levodopa) [16 . ]. With increasing dose, entacapone (1) decreased the COMT activity and 3-o-methyl-dopa concentrations, (2) prolonged the levodopa elimination t and increased the area under the curve, and (3) decreased the daily dose of levodopa, but (4) did not increase dyskinetic`on' time. It may thus be bene®cial to try doses beyond the recommended 200 mg/dose in patients with unsatisfactory¯uctuation.
The hypothesis that early use of COMT inhibitors would decrease the likelihood of developing untoward complications by stabilizing brain dopamine levels remains to be tested. It is expected that by 2003 a combination pill containing levodopa, DDI and COMT inhibitor will be available for clinical use.
Dopamine agonists
A variety of direct dopamine receptor agonists have been developed and licensed over the years: bromocriptine, lisuride, pergolide, cabergoline, pramipexole, and ropinirole are currently marketed oral agents, although not all in all countries. None of these stimulates the full complement of dopamine receptors in the same way as levodopa does; most stimulate D2-type (primarily D2 and D3) receptors [17] . Still, these agonists have been effective in patients at all stages of Parkinson's disease, and as monotherapy in patients with mild to moderate disease.
Several studies were published in the period immediately prior to that covered by this review, and have been summarized [18] . These studies demonstrate decreased probability of developing dyskinesias (as well as motor uctuations) in patients initially treated with a dopamine agonist rather than levodopa, even those patients who later received levodopa supplementation. There was a small but statistically signi®cant bene®t in measures of symptom/sign control (Uni®ed Parkinson's Disease Rating Scale, UPDRS) in those patients starting with levodopa rather than dopamine agonists. Most of these patients had the opportunity for levodopa supplementation if they felt their symptoms were not controlled satisfactorily, but did not elect this option. In addition, a 4-year follow-up of cohort of patients randomized to either pramipexole or levodopa for initial treatment of PD (the CALM-PD study) found that initial pramipexole (compared with levodopa) treatment was associated with a higher risk of freezing, somnolence, edema, and cellulitis, and there was no difference in quality of life [19] . Serial radionuclide imaging with markers for dopamine terminals have suggested a reduction in loss of dopamine terminals with both pramipexole [20 . . ] and ropinirole [21] compared with levodopa. Since in both studies patients seemed to experience greater improvement with levodopa than with a dopamine agonist, this suggests that some baseline of continuous dopaminergic stimulation with a dopamine agonist might provide enough protection against dyskinesias and that supplementing with levodopa for maximal clinical ef®cacy might be the best approach ± as has been suggested in primate studies [22] .
Direct comparison studies of the dopamine agonists are lacking, but a number of meta-analyses or literature comparisons have suggested that the various dopamine agonists have similar clinical effects but individual variations in a patient's response and tolerance usually determines which agonist will be used in a particular patient [23, 24] . Another recent study [25] found that high-dose ropinirole (20±36 mg/day) was well tolerated and conferred signi®cant clinical bene®t on patients with motor¯uctuations. Previous studies used a maximal ropinirole dose of 24 mg/day. Cabergoline is an interesting agent because its 72 h t allows oncedaily dosing. It is effective in treating motor symptoms as an add-on agent and after switching from another dopamine agonist [26] . Another analysis concluded that treatment with cabergoline showed`higher ef®cacy and greater safety than other parkinsonian drugs'; however, in a comparison of cabergoline versus bromocriptine [27] , cabergoline produced similar bene®ts to bromocriptine in`off' time reduction, motor impairment and disability ratings, and levodopa dose reduction over the ®rst 3 months of therapy. Until more direct head-tohead comparison studies are performed, it cannot be stated with any certainty that one agent is superior to another.
It is not clear what the ideal pharmacologic properties of the dopamine agonists are. Most or all of the currently available agonists are active at the D2 and D3 receptors. Conventional wisdom has held that stimulation of both D1-and D2-class receptors is required for full ef®cacy. Recent articles have shown that compounds that act only at D1 receptors have full ef®cacy; however, continuous administration of these compounds usually leads to tachyphylaxis and results differ on the propensity to induce dyskinesias [28, 29] . Currently, there is no full D1 agonist available for oral administration to undergo clinical trials, but several agonists are in clinical development [30] .
In contrast to the oral agents, apomorphine is an agonist at both D1-and D2-class dopamine receptors and may be better than other available agonists for the treatment of Parkinson's disease. The practical problems associated with this agent are its lack of oral bioavailability, short t and high incidence of peripheral side effects. The peripheral side effects generally require concomitant administration of domperidone, a peripheral D2 receptor blocker, which is not licensed in all countries. Continuous subcutaneous apomorphine infusion, although cumbersome, has been demonstrated to be effective over at least 5 years [31] . A recent trial demonstrated that the use of intermittent subcutaneous apomorphine injection [32] is effective and safe for outpatient use to reverse off-state events. Other routes of apomorphine administration, including nasal and sublingual [33] as well as a portable pump for IV infusion [34] , are also being investigated.
New dopamine agonist patch preparations, developed to avoid problems with pharmacokinetics and bioavailability, have been effective in reducing levodopa dosage in small add-on trials [35 . . ,36 . . ] and have shown ef®cacy as initial monotherapy in a multicenter, double-blind, randomized, placebo-controlled study involving 316 early idiopathic PD patients [37 . . ]. These preparations can be used to further test the strategy of continuous dopaminergic stimulation.
What is the next drug to administer to patients currently on therapy with levodopa and a decarboxylase inhibitor when they develop motor¯uctuations? Dopamine agonists (pergolide, pramipexole, and ropinirole) and COMT inhibitors (tolcapone and entacapone) were compared in a meta-analysis and found to be roughly comparable, but pramipexole and entacapone had the best ef®cacy and tolerability pro®le in this analysis [38] .
The great hope is that the dopamine agonists might be neuroprotective. In an open, randomized trial [39] of 782 patients with de-novo Parkinson's disease randomized to one of three treatment arms ± levodopa plus DDI; levodopa plus DDI and selegiline; or bromocriptine, using intention-to-treat analysis ± starting treatment with the dopamine agonist bromocriptine did not reduce mortality. A slightly lower incidence of motor complications was achieved at the expense of signi®cantly worse disability scores throughout the ®rst years of therapy.
By and large, the adverse effects of dopaminergic agents are similar. Although excessive daytime sleepiness is common in Parkinson's disease, all dopamine agonists have been additionally associated with excessive daytime sleepiness. The term`sleep attacks' has been used and is controversial [40±42]. Modafanil may help alleviate the excessive daytime sleepiness [43] . Bromo-criptine and pergolide have been associated with (pericardial, pleural and retroperitoneal) ®brosis, but ropinirole and pramipexole are not ergot alkaloids and have thus far not been associated with these complications [44] .
Non-dopaminergic approaches: glutamate
Glutamatergic inputs from the cortex and centromedian/ parafascicularis complex of the thalamus are funneled through the striatum to the globus pallidus then the thalamus and back to the cortex. The hyperactive STN also uses glutamate as a neurotransmitter. The interactions between glutamate receptors, cellular responses to glutamate and other transmitters are complex. Blockade of glutamate receptors has been proposed to be bene®cial both in mediating acute motor symptomatic effect and blockade of dyskinesias [45] .
Amantadine has long been used for its mild bene®cial effects on symptoms of Parkinson's disease and more recently as an antidyskinetic agent. It has dopaminereleasing and anticholinergic properties, as well as blocking glutamate N-methyl-D-aspartate (NMDA) receptors. A recent positron emission tomography (PET) study [46] suggests that in Parkinson's disease patients, amantadine does not produce an increase in extracellular levels of dopamine suf®cient to inhibit [ 11 C]raclopride binding to D2 receptors; therefore, it is likely that the primary effect of amantadine is on glutamate receptors. In one study, 15 days of amantadine (300 mg/day) as adjunctive therapy resulted in an average 38% reduction in dyskinesias [47] , although too rapid amantadine withdrawal resulted in severe, but reversible, hyperthermia. In addition, 200 mg of intravenous amantadine improved disabling levodopa-induced dyskinesias by 50% without any loss in the antiparkinsonian bene®t from levodopa [48] . Other agents that have been tested which directly or indirectly antagonize glutamate include remacemide [49, 50] and riluzole [51] , both ineffective in early trials, but long-term studies of a large number of patients are needed to answer the question as to whether these drugs have disease-modifying effects in Parkinson's disease.
Adenosine A2A receptors chronically and antagonistically interact with D2 receptors [52 . ]. Caffeine and theophylline are methylxanthine adenosine A2A receptor antagonists that enhance locomotor activity in animal models of parkinsonism [53 . ]. In a 10-patient doubleblind, crossover, placebo-controlled trial, intravenous theophylline at stable levels between 10 and 20 mg/ml, after 15 days of treatment [54] , induced a longer duration effect of levodopa in all UPDRS variables including dyskinesias. In the end, however, there was little effect of theophylline. Recently, potent and highly selective A2A receptor antagonists, such as KW-6002 [55] , have been tested as antidyskinetic agents, drugs that may improve motor function without exacerbating dyskinesias and exert neuroprotection in animal models of Parkinson's disease.
Other approaches
Stimulation of cannabinoid receptors enhances gaminobutyric acid transmission, including in the GPe, thought to be overactive in levodopa-induced dyskinesias. In a small randomized, double-blind, placebocontrolled, crossover trial the cannabinoid receptor agonist nabilone signi®cantly reduced levodopa-induced dyskinesia in Parkinson's disease [56] . a-2 Adrenoreceptor antagonists increase release of norepinephrine by autoreceptor blockade and reduce levodopa-induced, but not apomorphine-induced, dyskinesia in animals [57 . . ]. Idazoxan, an a-2 antagonist, improved severity of dyskinesia without diminishing antiparkinsonian response to levodopa [58 . . ]. Nicotine stimulates the release of dopamine in the striatum, and preserves nigral neurons and striatal dopamine levels in laboratory animals with lesioned nigrostriatal pathways. In a 12week, randomized, double-blind, placebo-controlled trial of the ef®cacy and tolerability of transdermal nicotine patches as an add-on treatment for cardinal symptoms of Parkinson's disease, there was no acute symptomatic effect [59] .
Functional surgery
Enthusiasm for surgery in Parkinson's disease continues to grow. Surgical interventions have targeted the Vim nucleus of the thalamus, STN or GPi, directly by an ablative procedure or indirectly by high-frequency deep brain stimulation (DBS). An earlier comparison of thalamic stimulation and ablation concluded they were essentially equivalent in their ef®cacy, but there were more side effects with lesions [60] . Clinical practice has shifted largely to DBS. Although DBS is expensive, one pharmacoeconomic analysis concluded it may be costeffective if it increases quality of life by more than 18% [61] .
Thalamic stimulation is effective for tremor, but does not help other features of Parkinson's disease [62] . DBS of the GPi and STN, however, may offer bene®ts by improving parkinsonian symptoms, smoothing out motor uctuations and reducing dyskinesias by allowing a decrease in daily levodopa dose. The DBS study group [63 . . ] performed a prospective, double-blind study in patients with advanced Parkinson's disease, in whom electrodes were implanted bilaterally in the STN (96 patients) or GPi (38 patients); the choice of surgical target was not randomized. Three months after the procedures were performed, stimulation of the STN was associated with a median improvement in the UPDRS motor score (as compared with no stimulation) of 49%, and stimulation of the GPi with a median improvement of 37%. Between the preoperative and 6 month visits, on' time without involuntary movements increased from 27 to 74% of the day with STN stimulation and from 28 to 64% with GPi stimulation. Adverse events included intracranial hemorrhage in seven patients and infection necessitating removal of the leads in two. In addition, there was about a 40% decrease in levodopa equivalents in the STN group but none in the GPi. Virtually the same results were obtained in other longer but smaller studies [64, 65] .
Intraoperative recording, a procedure that adds cost, time and possibly increased risk of bleeding to surgery, is necessary for accurate electrode placement. In a particularly well carried out study, the most effective contact of a quadripolar electrode was always in the upper part of the STN recording area or immediately above it [66 . ], which corresponds to the sensorimotor portion of the nucleus in humans [67 . . ]. In a combined physiologic/imaging study [66 . ], the STN boundaries were identi®ed intraoperatively by recording neuronal electrical activity and the quadripolar electrode was positioned to locate at least two contacts within the STN recording area. Intraoperative macrostimulation was performed to con®rm the correct position of the electrode. Clinical evaluation of the effects of stimulation was checked for each contact of the quadripolar electrode, testing the improvement in contralateral rigidity to select the best contact immediately after surgery and at 3 months and 1 year after surgery. In 35.7% of the procedures it was necessary to perform more than one track to get a recording of neuronal activity consistent with STN. This strongly suggests that only anatomic guidance without the bene®t of a microelectrode recording would result in a suboptimal electrode placement.
Valuable experience has been gained with maintenance programming of the stimulators. It has been easier to program stimulators placed in the Vim for tremor because tremor responds within seconds to stimulator adjustments. Conventional wisdom has held that the therapeutic response in the STN takes hours to days. While this may be true for reduction of bradykinesia, reduction in rigidity occurs within seconds to minutes. This observation allows for more ef®cient adjusting and testing of various stimulation parameters. With experience, most centers ®nd that monopolar stimulation with relatively short pulse widths and frequency above 100 Hz is optimal; this has been con®rmed systematically [68 . . ].
What clinical effect does DBS have? There is some debate as to whether DBS reduces motor¯uctuations by reducing disability in the drug-off state or by alterations in levodopa pharmacodynamics, although the former explanation is favored by most [69] . A number of studies have demonstrated that STN DBS affects the cardinal motor features of Parkinson's disease. In addition, STN DBS improves several acoustic features of the voice but not its volume [70] . Walking velocity in Parkinson's disease is reduced mainly due to reduction in stride length, while cadence (steps/min) is slightly enhanced. Chronic bilateral STN stimulation, like treatment with levodopa, is associated with an increase in stride length, while cadence is unchanged. Stride length and velocity with STN stimulation alone are increased into the range of normal controls [70] ; however, in a combined quantitative and qualitative study of gait, chronic bilateral GPi stimulation provided only limited effects in the`off' condition [71] . DBS, while effective, is labor intensive, time consuming and dependent on expert knowledge of the disease and its pharmacology and treatment. This raises the question as to whether ablative procedures are suf®ciently effective that they can be employed in situations where DBS is unavailable. Pallidotomy improves cardinal features of Parkinson's disease while reducing dyskinesias in 6±8 month studies [72] . Long-term (i.e. 410 year) follow-up of pallidotomy [73] has been reported in 13 consecutive patients. Dosages of dopaminergic agents were increased in all patients, without recurrence or induction of dyskinesias contralateral to the pallidotomy. Contralateral tremor, if initially controlled by surgery, remained improved; however, most patients exhibited a gradual recurrence of akinesia and an increase in gait freezing. Further progression of axial and akinetic symptoms, and an eventual decline in cognition together with other concomitant illnesses, contributed to increased disability in several patients. Subthalamotomy has also been explored, and found to be effective. The threat of ballismus has dampened enthusiasm for this procedure, although there is a debate as to its frequency and whether in fact patients with Parkinson's disease have a decreased propensity to develop this condition after a STN lesion [74 . . , 75, 76] . Of interest is the fact that, in an unplanned approach, if a stimulator that is effective must be removed, a lesion can be made with good effect through that stimulating electrode before removing the leads [77] . Long-term studies, however, may show that downstream bene®ts produced by chronic stimulation are important in the course of the disease and cannot be reproduced by the ®xed effect of a lesion.
Neural restoration
Transplantation of dopaminergic tissues has been performed since this was shown to be ef®cacious in rodent Parkinson's disease models. Initially, this involved open clinical trials of autologous adrenal tissue and other peripheral sympathetic tissue [78] and heterologous fetal mesencephalon tissue. Finally, the results were released of the ®rst double-blind trial involving a sham surgery control [79 . . ]. Forty patients (34±75 years of age) with severe Parkinson's disease were randomly assigned to receive a transplant of nerve cells (cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally) or sham surgery and followed in a double-blind manner for 1 year. In the patients who received sham surgery, holes were drilled in the skull but the dura was not penetrated. There was no difference between groups in the primary outcome variable ± subjective global rating of the change in the severity of disease. Among younger patients (460 years old), there was improvement in standardized tests of Parkinson's disease in the transplantation group as compared with the sham-surgery group: the UPDRS motor score in the practically de®ned`off' state. Fiber outgrowth was detected in 17 of the 20 patients in the transplantation group, as indicated by an increase in 18 Fuorodopa uptake on PET or postmortem examination. After improvement in the ®rst year, dystonia and dyskinesias recurred in 15% of the patients who received transplants, even after reduction or discontinuation of the dose of levodopa. One year following surgery, there was a 40.3% increase in¯uorodopa uptake in the putamen of the group receiving implants compared with the placebo surgery patients in both age groups [80] . Correlations between the PET changes and clinical outcome were signi®cant only in the younger patient subgroup (r = 0.58). The ®ndings suggest that human embryonic dopamine-neuron transplants survive in patients with severe Parkinson's disease and result in some clinical bene®t in younger but not in older patients. Patient age does not in¯uence graft viability or development in the ®rst year after surgery; however, host age may in¯uence the time course of the downstream functional changes that are needed for clinical bene®t to occur. The results of a simultaneously funded study, which has already been completed, remain to be published.
Although this double-blind, sham surgery controlled study was hailed as a methodologic ®rst, it was generally interpreted as a negative result. In a meta-analysis of other similar, but not controlled studies of fetal transplantation, the magnitude of the effect in the controlled trial (i.e. on the UPDRS score) was shown to be comparable to previous reports and the clinical improvement continues well beyond a year [81] . The fact that the transplant is taking up¯uorodopa does not necessarily indicate that the cells have matured and made synaptic contacts. There are technical and other issues that remain unresolved. For example, are additional agents such as trophic factors or neuroimmunophilins required to enhance graft survival and differentiation? [82] .
Though fetal human dopamine transplantation has had at least some success in concept, the following remaining problems make this a dif®cult practical strategy: dif®culty recovering fragments of fetal brain tissue from elective abortions and 90±95% of transplanted neurons failing to survive with most dying by apoptotic program cell death. Dopamine neurons generated in tissue culture and, ultimately, stem cells, which remain relatively undifferentiated, might represent an answer to both of these problems [83 . . ], although many challenging issues still remain [84] .
Dystonia
Dystonia can be a signi®cant part of Parkinson's disease [85] . It may be seen in isolation or as part of a spectrum of levodopa-associated complications. Systemic agents, baclofen and anticholinergics are often effective but can have systemic side effects. Local treatment with botulinum toxin can often be effective without eliciting signi®cant systemic side effects. Botulinum toxin is effective in treating many facets including clenched ®st, blepharospasm/apraxia of lid opening, anismus, and possibly freezing [85] .
Nonmotor manifestations of Parkinson's disease
Besides the dopamine system, other neurotransmitter systems are affected in Parkinson's disease, including serotonin. Using ( 123 )I-2b-carboxymethoxy-3b-(4-iodophenyl)tropane (b-CIT) single photon emission computed tomography reduced striatal binding ratios (re¯ecting regional dopamine transporter densities) and were associated with motor symptoms, while dorsal midbrain binding ratios (re¯ecting regional serotonin transporter densities) were signi®cantly correlated with alterations of mentation, behavior, and mood [86] . These ®ndings suggest that degeneration of the nigrostriatal dopaminergic neurons and a dysfunctional serotonergic raphe system contribute differentially to motor de®cits and neuropsychiatric symptoms in Parkinson's disease. Although selective serotonin reuptake inhibitors, as well as newer agents such as venlefaxine, mirtazipine and bupropion, are recommended in Parkinson's disease, there are no comparison data. In patients without Parkinson's disease but with depression, pramipexole was shown to have an antidepressant effect comparable to¯uoxetine [87] .
Psychosis is seen in Parkinson's disease as an apparent complication of treatment; however, it is also present in some patients on no or very low doses of medication [88± 90], the latter being suggestive of dementia with Lewy bodies. The working hypothesis has been that the psychosis is due to stimulation of dopamine receptors. Treatment in the past has employed conventional antipsychotics, which typically block D2 dopamine receptors and tend to worsen primary Parkinson's disease features. Atypical antipsychotics have the advantage of not worsening the Parkinson motor symptoms. Clozapine remains the best medication for this, as demonstrated by the recent report on an extension to a previous trial [91] ; however, the albeit low tendency to cause agranulocytosis makes its use problematic. Newer atypical antipsychotics have been tested in this regard. Olanzapine 5±10 mg can be effective without worsening motor features in patients with Parkinson's disease (dementia with Lewy bodies in this case) [92] . Amoxapine carries a relatively low risk of parkinsonism but has been shown to cause deterioration in Parkinson's disease motor features when used as an antipsychotic [93] .
Another approach to treatment of behavioral problems has been the use of anticholinesterases, which can improve neuropsychiatric dysfunction as well as cognition. This was shown in a double-blind, randomized, placebo-controlled trial in dementia with Lewy bodies [94] and an open trial in Parkinson's disease with psychosis [95] .
Conclusion
Options for treatment of Parkinson's disease depend on the individual's symptomatology [8 . ,96 . . ]. For the patient with mild Parkinson's disease, whose symptoms are not functionally disabling, current options include the use of nonpharmacologic therapies (education, exercise). There is no current evidence to support any agent as a neuroprotective therapy. It is not unreasonable, however, to use selegiline, as it does delay the need for levodopa.
For the patient with functional disability, symptomatic treatment is usually needed. The clinician faces the decision of using levodopa or a dopamine agonist. Levodopa has a statistically greater effect, although in relatively mild disease, Hoehn and Yahr stage 1 or 2, the magnitude of this difference is small. Levodopa may have less neurobehavioral side effects in patients with mild cognitive impairment, such as the elderly. Alternatively, dopamine agonists have a lower incidence of motor complications, especially dyskinesia. Many would treat patients below a certain age (e.g. 65 years) with an agonist and above this age with levodopa; however, one can argue the case for trying almost anyone on an agonist and if adverse effects develop, since they are virtually always reversible, switch to levodopa. With signi®cant functional impairment that may adversely impact on one's livelihood, a case can be made for treating even younger patients with levodopa, since one can get a better and faster effect. Although titration of levodopa can be performed faster than that generally recommended for agonists, it is possible to greatly accelerate the upward titration of agonists. One can then add levodopa as necessary. Generally, treatment of Parkinson's disease symptoms is not something that has to be done over a few weeks; weighing up the risks and bene®ts of these treatments in any individual patient's life must be done on a case-by-case basis. In patients with tremor predominant disease, some might start with an anticholinergic, however the overall effect on tremor is as good with a dopamine agonist [97], the side effects tend to be less, and the dopamine agonist also improves other symptoms of Parkinson's disease, particularly bradykinesia. Amantadine is another useful drug in the early phases of treatment, but side effects such as ankle edema, livedo reticularis, psychosis, confusion, and urinary retention may occur, particularly in the elderly.
The person with more advanced disease, with motor uctuations and dyskinesias, generally requires polypharmacy with levodopa, a COMT inhibitor and an agonist. Amantadine can be used in addition to combat dyskinesias. Patients at this stage of disease generally warrant consideration of surgery. DBS of the STN seems the preferred procedure. The other group that bene®ts from surgery and should be considered earlier for this option are levodopa-intolerant patients [98 . . ].
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